Lutetium, actinium or lead: Can isotope type offer an edge in radiotherapy?
Once considered a niche cancer therapy, radioligands are in the midst of a renaissance.
“If you think about where ADCs were four or five years ago, that’s roughly where radioligand therapies [RLT] are now,” Novartis’ head of radioligand therapies Jeevan Virk told Endpoints News in an interview. Novartis is one of the big names in the space, with the US approvals of Lutathera and Pluvicto in 2018 and 2022, respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.